Cellectar director granted 25,000 stock options

Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock.

Rhea-AI Filing Summary

Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock. The options were awarded at an exercise price of $2.70 per share and expire on July 7, 2036. Following this grant, he holds options for 25,000 shares.

According to the footnote, the option vests in full on July 7, 2027, subject to his continued service through that vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider NEIS JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 25,000 options Exercise price: $2.70 per share Post-grant option holdings: 25,000 options +2 more

5 metrics

Options granted 25,000 options Stock option grant to director John Neis

Exercise price $2.70 per share Strike price of stock option grant

Post-grant option holdings 25,000 options Total options held following transaction

Vesting date July 7, 2027 Options vest in full on this date

Expiration date July 7, 2036 Option term end date

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, exercise price, vesting date, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 2.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date financial

"shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date"

expiration date financial

"expiration_date: 2036-07-07T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cellectar Biosciences (CLRB) director John Neis report on this Form 4?

Director John Neis reported receiving a grant of stock options for 25,000 Cellectar Biosciences shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.

How many Cellectar Biosciences (CLRB) options were granted to John Neis and at what price?

John Neis was granted stock options covering 25,000 Cellectar Biosciences shares at an exercise price of $2.70 per share. This grant provides potential future ownership if exercised at or above that strike price.

When do John Neis’s Cellectar Biosciences (CLRB) stock options vest and expire?

The stock options granted to John Neis vest in full on July 7, 2027, subject to his continued service. The options have an expiration date of July 7, 2036, giving him a long window to exercise after vesting.

Is the Cellectar Biosciences (CLRB) Form 4 for an open-market trade or an option grant?

The Form 4 reports an option grant, not an open-market trade. The transaction uses code “A” for a grant or award acquisition of 25,000 stock options, representing compensation rather than a market purchase or sale of existing shares.

How many Cellectar Biosciences (CLRB) options does John Neis hold after this transaction?

After this transaction, John Neis holds stock options for 25,000 Cellectar Biosciences common shares directly. The filing does not list other derivative holdings, so this grant represents his reported option position in this specific Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEIS JOHN

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.7	07/07/2026		A		25,000		(1)	07/07/2036	Common stock	25,000	$0	25,000	D

Explanation of Responses:

1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Chad Kolean, attorney-in-fact for John Neis	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)